Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Gebremedhin Beedemariam GebretekleAtalay Mulu FentieGirma Tekle GebremariamEskinder Eshetu AliDaniel Asfaw ErkuTinsae AlemayehuWorkeabeba AbebeBeate SanderPublished in: BMC health services research (2022)
Our study showed that the use of caspofungin as primary treatment for IC/C in Ethiopia was not cost-effective when compared with fluconazole-initiated treatment alternatives. The findings supported the use of fluconazole-initiated therapy with caspofungin as a second-line treatment for patients with IC/C in Ethiopia.